PEDRO ENRIQUE DORLHIAC LLACER
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
7 resultados
Resultados de Busca
Agora exibindo 1 - 7 de 7
bookPart Leucemias e doenças mieloproliferativas(2013) LLACER, Pedro Enrique Dorlhiac- POLYCLONAL OUTBREAK OF BLOODSTREAM INFECTIONS CAUSED BY Burkholderia cepacia COMPLEX IN HEMATOLOGY AND BONE MARROW TRANSPLANT OUTPATIENT UNITS(2014) BOSZCZOWSKI, Icaro; PRADO, Gladys Villas Boas do; DALBEN, Mirian F.; TELLES, Roberto C. P.; FREIRE, Maristela Pinheiro; GUIMARAES, Thais; OLIVEIRA, Maura S.; ROSA, Juliana F.; SOARES, Robson E.; LLACER, Pedro Enrique Dorlhiac; DULLEY, Frederico Luiz; COSTA, Silvia F.; LEVIN, Anna S.Aim: The objective was to describe an outbreak of bloodstream infections by Burkholderia cepacia complex (Bcc) in bone marrow transplant and hematology outpatients. Methods: On February 15, 2008 a Bcc outbreak was suspected. 24 cases were identified. Demographic and clinical data were evaluated. Environment and healthcare workers' (HCW) hands were cultured. Species were determined and typed. Reinforcement of hand hygiene, central venous catheter (CVC) care, infusion therapy, and maintenance of laminar flow cabinet were undertaken. 16 different HCWs had cared for the CVCs. Multi-dose heparin and saline were prepared on counter common to both units. Findings: 14 patients had B. multivorans (one patient had also B. cenopacia), six non-multivorans Bcc and one did not belong to Bcc. Clone A B. multivorans occurred in 12 patients (from Hematology); in 10 their CVC had been used on February 11/12. Environmental and HCW cultures were negative. All patients were treated with meropenem, and ceftazidime lock-therapy. Eight patients (30%) were hospitalized. No deaths occurred. After control measures (multidose vial for single patient; CVC lock with ceftazidime; cleaning of laminar flow cabinet; hand hygiene improvement; use of cabinet to store prepared medication), no new cases occurred. Conclusions: This polyclonal outbreak may be explained by a common source containing multiple species of Bcc, maybe the laminar flow cabinet common to both units. There may have been contamination by B. multivorans (clone A) of multi-dose vials.
bookPart Leucemia mieloide aguda(2016) YAMAKAWA, Patricia Eiko; VELLOSO, Elvira Deolinda Rodrigues Pereira; LLACER, Pedro Enrique DorlhiacbookPart Exame clínico no paciente hematológico(2016) CHAMONE, Dalton de Alencar Fischer; LLACER, Pedro Enrique DorlhiacbookPart Emergências Relacionadas às Leucemias e Síndrome de Hiperviscosidade(2013) ZEINAD, Audrey Kruse; LLACER, Pedro Enrique DorlhiacconferenceObject Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd(2014) LARSON, Richard A.; KIM, Dong-Wook; ISSARAGRILSIL, Surapol; COUTRE, Philipp le; LLACER, Pedro Enrique Dorlhiac; ETIENNE, Gabriel; CLARK, Richard E.; FLINN, Ian; NAKAMAE, Hirohisa; HOCHHAUS, Andreas; SAGLIO, Giuseppe; KANTARJIAN, Hagop M.; DONOHUE, Breanne; DENG, Weiping; MENSSEN, Hans D.; HUGHES, Timothy P.- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib(2014) HUGHES, Timothy P.; LIPTON, Jeffrey H.; SPECTOR, Nelson; CERVANTES, Francisco; PASQUINI, Ricardo; CLEMENTINO, Nelma Cristina D.; LLACER, Pedro Enrique Dorlhiac; SCHWARER, Anthony P.; MAHON, Francois-Xavier; REA, Delphine; BRANFORD, Susan; PURKAYASTHA, Das; COLLINS, LaTonya; SZCZUDLO, Tomasz; LEBER, BrianPatients in complete cytogenetic response (CCyR) with detectable BCR-ABL1 after >= 2 years on imatinib were randomized to nilotinib (400 mg twice daily, n = 104) or continued imatinib (n = 103) in the Evaluating Nilotinib Efficacy and Safety in clinical Trials-Complete Molecular Response (ENESTcmr) trial. By 1 and 2 years, confirmed undetectable BCR-ABL1 was achieved by 12.5% vs 5.8% (P = .108) and 22.1% vs 8.7% of patients in the nilotinib and imatinib arms, respectively (P = .0087). Among patients without molecular response 4.5 (BCR-ABL1(IS) <= 0.0032%; MR4.5) and those without major molecular response at study start, MR4.5 by 2 years was achieved by 42.9% vs 20.8% and 29.2% vs 3.6% of patients in the nilotinib and imatinib arms, respectively. No patient in the nilotinib arm lost CCyR, vs 3 in the imatinib arm. Adverse events were more common in the nilotinib arm, as expected with the introduction of a new drug vs remaining on a well-tolerated drug. The safety profile of nilotinib was consistent with other reported studies. In summary, switching to nilotinib enabled more patients with chronic myeloid leukemia in chronic phase (CML-CP) to sustain lower levels of disease burden vs remaining on imatinib. This trial was registered at www. clinicaltrials.gov as # NCT00760877.